Julie Ehlers

5 days ago | cancertherapyadvisor.com | Julie Ehlers

The American Society of Clinical Oncology (ASCO) and the Society for Neuro-Oncology (SNO) have updated their guidelines for adults with grade 2, IDH-mutant oligodendroglioma or astrocytoma to include guidance on the use of vorasidenib.1 The updated guidelines were published in the Journal of Clinical Oncology.

2 weeks ago | cancertherapyadvisor.com | Julie Ehlers

Using both liquid and tissue biopsies to guide targeted treatment may improve outcomes in patients with solid tumor malignancies, according to results from the ROME trial presented at the AACR Annual Meeting 2025. This phase 2 trial (NCT04591431) enrolled patients with advanced solid tumors who had received no more than 2 lines of histology-based standard therapy. All patients underwent genomic profiling via tissue and liquid biopsies.

3 weeks ago | medicalbag.com | Julie Ehlers

The American Cancer Society (ACS) has released cancer statistics for 2025, which suggest that more than 2 million new cases of cancer will be diagnosed in the United States this year, and more than 600,000 people will die of cancer. These and other projections were published in CA: A Cancer Journal for Clinicians. Researchers estimate that, in 2025, there will be 2,041,910 new cancer diagnoses in the US, which works out to about 5600 new cases each day.

3 weeks ago | cancertherapyadvisor.com | Julie Ehlers |Jen Smith |Mark L. Fuerst |Rachelle R. Ramsey

Cancer apps — smartphone applications targeted to cancer patients — can be helpful tools, keeping patients informed about their disease, helping them track their medications and symptoms, and facilitating connections with health care providers and other patients.1-3  Experts note, however, that cancer apps have limitations and may even be detrimental in certain cases.

2 months ago | oncologynurseadvisor.com | Julie Ehlers

Adding 177Lu-PSMA-617 to enzalutamide improves survival and quality of life in patients with metastatic castration-resistant prostate cancer (mCRPC) who are at risk of early treatment failure with enzalutamide alone, according to research presented at the ASCO Genitourinary Cancers Symposium 2025.1These results come from the phase 2 ENZA-p study (NCT04419402), which enrolled 162 patients with mCRPC who had not received chemotherapy.